Roche and Trimeris announce the submission of the Marketing Authorisation Application to the EU for Fuzeon (enfuvirtide, T-20) for HIV-1 infection in combination with other antiretroviral agents. This follows three days after announcing the filing of a New Drug Application for Fuzeon with the US FDA. Roche and Trimeris also confirm the achievement of an important production milestone at the Roche Colorado manufacturing facility –completion of three validation batches of the active ingredient for Fuzeon. These were successfully achieved despite the enormous challenges of manufacturing such a complex molecule at large scale. The EU and US submissions are based on the outstanding phase III results, which generated considerable interest when presented at the recent International Aids Congress. The data are better than expected and show that extensively treatment experienced patients are twice as likely to achieve undetectable HIV levels plus have an improved immunological response when Fuzeon is combined with other antiretroviral agents compared to taking antiretroviral agents without Fuzeon.

"Patients are now living with new and different types of HIV – and as the virus constantly evolves we need dramatically different therapies to help combat it" said Dr. Bonaventura Clotet, Head of HIV Section, Hospital Germans Trias i Pujol, Spain. "The need for this new class of drug is becoming increasingly urgent as we are faced with the disturbing statistic that up to 78 percent of patients in Europe have a strain of the HIV virus that has developed resistance to one or more anti-HIV drugs. "Fuzeon takes a completely new approach to fighting the virus by blocking HIV entry into healthy immune cells – a significant step in the battle against HIV resistance".

Fuzeon is the frontrunner in a new class of anti-HIV drugs called "fusion inhibitors". Unlike existing anti-HIV drugs that work inside the cell, Fuzeon has a unique mode of action designed to block HIV before entering the human immune cell. Fuzeon is active against HIV that is resistant to the currently available classes of anti-HIV drugs. As a result of the better than expected activity and tolerability data, Fuzeon offers new hope to patients with limited treatment options.

"These filings are important steps for Roche." said Dr. David Reddy, HIV Franchise Leader, Roche. "Drug resistance has become one of the greatest HIV medical challenges physicians and patients are facing in the developed world today – and this in combination with the better-than-expected results for Fuzeon may lead to a potentially higher than initially anticipated demand for the drug. However, we are committed to ensure that all patients who have initiated therapy will receive an uninterrupted supply of Fuzeon. Fuzeon was one of the most difficult scientific and manufacturing challenges we have faced, but despite these challenges we developed Fuzeon at the fastest pace possible, in parallel across Europe and North America and now anticipate approvals from the first quarter next year."

"Fuzeon is designed to inhibit HIV replication in a completely different manner than current antiretroviral drugs. Furthermore, Fuzeon does not substantially add to the toxicity of other agents. Fuzeon's unique mode of action blocks HIV before entering the human immune cell and if approved, it will represent the first of a new class of anti- HIV drug in seven years," said Dr. Dani Bolognesi, CEO, Trimeris. "This European milestone is the latest result of the ongoing joint development programme between Roche and Trimeris."

Fuzeon is one of the most challenging molecules ever chemically manufactured at such a large scale by the pharmaceutical industry. One hundred and six manufacturing steps are required to produce the active drug substance alone, which is around ten times more than that of a protease inhibitor. To coincide with the fast paced clinical development program, the Roche Colorado manufacturing plant has been working 24 hours a day, seven days a week in the commercial scale-up of Fuzeon. Because of this dedication, the next major milestone for commercial manufacturing completion of three validation batches has been achieved and therefore, the process of bringing the commercial plant on hand for launch remains firmly on track. In addition, continued investments are being made in the ongoing development of the manufacturing facility to meet potential increased demand for Fuzeon.

--Ends--

It is estimated that in a single person the virus can mutate to form around a billion new and different versions of HIV in just 24 hours. The incidence of drug resistant HIV among already treated patients is increasing at a disturbing rate, with up to 78 percent of patients in North America and Europe infected with a strain of the virus that has developed resistance to one or more anti-HIV drug.

Roche is at the forefront of efforts to combat HIV infection and AIDS, committed since 1986 to groundbreaking research and development of innovative new drugs and diagnostic technology. Saquinavir was the first Protease Inhibitor (PI) and was first introduced by Roche in 1995 in the US.

As a consequence of Roche's continuous research and development, the combination of boosted saquinavir with ritonavir (1000/100 mg twice daily) has shown encouraging results in the MaxCmin 1 trial with high efficacy and an excellent safety and tolerability profile. Saquinavir/r was approved in the EU in August 2002. Viracept (nelfinavir), another PI is supplied by Roche outside the US and Canada. In first-line HIV therapy, Viracept delivers consistent long-term efficacy and safety. When used first line, Viracept also allows the subsequent use of both NNRTIs and other PIs for most patients due to its unique resistance pattern.

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals and diagnostics. Roche's innovative products and services address prevention, diagnosis and treatment of diseases, thus enhancing people's well being and quality of life.

Trimeris Safe Harbor Statement

Note: Except for any historical information presented herein, matters presented in this release are forward-looking statements that involve risks and uncertainties. The results of Trimeris’ previous clinical trials are not necessarily indicative of future clinical trials, and future results could differ materially from the results presented herein. Factors that could cause of contribute to such differences include, but are not limited to, those discussed in the "Risk Factors" section included in Trimeris’ Form S-3 filed with the Securities and Exchange Commission on August 23, 2002.

All trademarks used or mentioned in this release are legally protected.